Clinical Trials Browser

Active not recruiting × Clear-cell metastatic renal cell carcinoma × lenvatinib × Clear all

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 2 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell